Welcome!
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
Dr. Luis Raez, MD FACP FCCP, Chief of Hem/Onc and Med. Dir. at Memorial Cancer Institute, and Clinical Associate Prof. of Medicine at FL International University discusses Liquid Biopsies for Broad Next Generation Sequencing Testing.
Dr. Luis Raez, MD FACP FCCP, Chief of Hem/Onc and Med. Dir. at Memorial Cancer Institute, and Clinical Associate Prof. of Medicine at FL International University discusses Liquid Biopsies for EGFR.
Dr. Luis Raez, MD FACP FCCP, Chief of Hem/Onc and Med. Dir. at Memorial Cancer Institute, and Clinical Associate Prof. of Medicine at FL International University discusses Multiple Immunotherapy Agents.
Dr. Luis Raez, MD FACP FCCP, Chief of Hem/Onc and Med. Dir. at Memorial Cancer Institute, and Clinical Associate Prof. of Medicine at FL International University discusses evolving options in first line treatment of ALK-Positive non-small cell lung cancer (NSCLC).
Dr. Luis Raez, MD FACP FCCP, Chief of Hem/Onc and Med. Dir. at Memorial Cancer Institute, and Clinical Associate Prof. of Medicine at FL International University discusses First Line Immunotherapy for Advanced Non-Small Cell Lung Cancer NSCLC.
Support and the Caregiver Caring for a Caregiver When test reports come in, and the building anticipation confirms the worst fears with a diagnosis of...
Our mission has always been focused on health equity, patient education, and patient empowerment as a means to break down barriers and create...
We are continuing to edit the extensive videos from our 8th annual live patient forum, to make them available for our community! During this event...
Hi All, Our free, live, online Targeted Therapies Patient Forum is this coming Saturday July 15, 2023. Register here See the agenda here See you there...
Hi All, Our free, live, online Targeted Therapies Patient Forum is this coming Saturday July 15, 2023. Register here See the agenda here See you there...
Hi all - wondering if anyone has good experience with pulsed Tagrisso (taking 480-560mg once every week) for EGFR+ leptomeningeal disease (LMD)? We...
Hi there -- I am Denise Brock - the Operations Director for GRACE, the Global Resource for Advancing Cancer Education. I began working with Jack West...
Stephen Liu, MD provides updates to our Lung Cancer Video Library. In this recent video, Dr. Liu discusses current standards for Molecular Testing At Initial Diagnosis Of Advanced Non-Small Cell Lung Cancer (NSCLC).
We are pleased to have GRACE’s Jack West, MD, Medical Director, Thoracic Oncology Program, Swedish Cancer Institute in Seattle, Washington, and President and CEO of GRACE bring 2017 updates to our Lung Cancer Video Library.
In this latest video, Dr. West discusses advances in NSCLC – Timing Of Discussion Of Maintenance Therapy In First Line Treatment for Lung Cancer.
Written by Joshua Bauml, MD
September 2017
“Head and neck cancer” is an umbrella term for different cancers that occur in the head and neck region, from the sinuses and nasal cavity down to the larynx. The most common of these tumors affect the lining of the mouth and throat. Head and neck cancers are divided by where they start:
Oral cavity (tongue, gums, inner cheek)
For this series, GRACE sat down with Marco Ruiz, MD, an oncologist at Memorial Cancer Institute specializing in hematologic or blood cancers, including leukemia, lymphoma, myelodysplastic syndrome (MDS) and myelofibrosis. He is also an experienced bone marrow transplant specialist and is active in cancer research.
Jack West, MD, President and CEO of GRACE provides updates to our Lung Cancer Video Library. In this recent video, Dr. West discusses advances in NSCLC - Timing Of Discussion Of Maintenance Therapy In First Line Treatment for Lung Cancer
Jack West, MD, President and CEO of GRACE provides updates to our Lung Cancer Video Library. In this recent video, Dr. West discusses PDL1 as a biomarker for first line.
Download the speaker presentations and handouts from the Targeted Therapies Patient Forum in Cleveland at the Taussig Cancer Center on September 16, 2017.
Progress in understanding DNA changes in lymphoma has already provided improved and highly sensitive tests for detecting this disease. Such tests can identify lymphoma cells based on changes such as chromosome translocations or rearrangements or specific gene mutations. Some of these tests are already in use, and others are being developed. They may be used to:
On Saturday, September 16, 2017, patients, caregivers, family members and friends joined GRACE in Cleveland at the Taussig Cancer Center for a full day of discussion on Targeted Therapies in Lung Cancer. We are thrilled that people joined us for this amazing and informative day. Huge thanks to all of the faculty who spent their Saturday in Cleveland with our community, and thanks also to those organizations who sponsored this event - Astra Zeneca, Takeda, Boehringer Ingelheim, Ignyta, Novartis, Genentech, Caris, and Guardant Health.
Drs. H. Jack West, Matthew Gubens, and Jyoti Patel, gathered post ASCO 2017 to discuss new information regarding lung cancer. In this video, the doctors discuss Are MET Mutations Now a Mutation We Should Look for in Lung Cancer?
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.